Literature DB >> 6633501

Muscarinic stimulation of phosphatidylinositol metabolism in atria.

S L Brown, J H Brown.   

Abstract

Phosphatidylinositol (PtdIns) turnover in murine atria is stimulated by the cholinergic agonist carbachol. Incorporation of either [32P]phosphate or [myo-3H]inositol into PtdIns is increased 40-80% by 30 microM carbachol, but carbachol does not increase the labeling of other major phospholipids. Cholinergic stimulation of PtdIns synthesis is blocked by the muscarinic antagonist atropine. When Ca2+ is removed from the extracellular medium, there is a large increase in basal PtdIns synthesis, and carbachol does not produce any further increase in [32P]phosphate incorporation. Carbachol also stimulates hydrolysis of phosphoinositides as measured by myo[3H]inositol 1-phosphate accumulation. A maximal concentration of carbachol causes a 300-400% increase in phosphoinositide breakdown, and half-maximal stimulation occurs at a carbachol concentration of approximately 10 microM. Muscarinic stimulation of inositol phospholipid hydrolysis is seen in left and right atria as well as in ventricular tissue. The effect of carbachol on phosphoinositide hydrolysis is markedly attenuated when extracellular Ca2+ is removed. In contrast to most other hormone receptors linked to PtdIns metabolism, there is no evidence that cardiac muscarinic receptors mediate their physiological effects through Ca2+ mobilization. Thus, receptor-mediated changes in PtdIns turnover may serve a different function in the heart than in hormone-receptor systems that utilize Ca2+ as a second messenger.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6633501

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  20 in total

Review 1.  Selective updates on mechanisms of action of positive inotropic agents.

Authors:  G Grupp
Journal:  Mol Cell Biochem       Date:  1987-08       Impact factor: 3.396

2.  Increased insulin secretion by muscarinic M1 and M3 receptor function from rat pancreatic islets in vitro.

Authors:  T R Renuka; Remya Robinson; C S Paulose
Journal:  Neurochem Res       Date:  2006-05-03       Impact factor: 3.996

3.  Neuronal membrane depolarization and the control of cholinergic muscarinic receptors: selective effect on different neuronal cell types.

Authors:  R Simantov; R Levy
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

Review 4.  Inositol trisphosphate and diacylglycerol as second messengers.

Authors:  M J Berridge
Journal:  Biochem J       Date:  1984-06-01       Impact factor: 3.857

5.  Nitroglycerin-induced desensitization of vascular smooth muscle may be mediated through cyclic GMP-disinhibition of phosphatidylinositol hydrolysis.

Authors:  J K Chuprun; R M Rapoport
Journal:  Experientia       Date:  1987-03-15

6.  Effects of carbachol and (-)-N6-phenylisopropyladenosine on myocardial inositol phosphate content and force of contraction.

Authors:  C Kohl; B Linck; W Schmitz; H Scholz; J Scholz; M Tóth
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

Review 7.  The role of endothelium in the control of vascular tone.

Authors:  R Busse; G Trogisch; E Bassenge
Journal:  Basic Res Cardiol       Date:  1985 Sep-Oct       Impact factor: 17.165

Review 8.  Second messengers involved in the muscarinic control of the heart: the role of the phosphoinositide response.

Authors:  J N Hawthorne; S H Simmonds
Journal:  Mol Cell Biochem       Date:  1989-09-07       Impact factor: 3.396

9.  Possible mechanisms of inhibition with atropine against noradrenaline-induced contraction in the rabbit aorta.

Authors:  N Satake; S Kiyoto; S Shibata; V Gandhi; D J Jones; M Morikawa
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

10.  The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles.

Authors:  Jaromir Myslivecek; Martin Klein; Martina Novakova; Jan Ricny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-29       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.